Cue Biopharma
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.65
- Today's High:
- $2.7701
- Open Price:
- $2.69
- 52W Low:
- $2.18
- 52W High:
- $5.12
- Prev. Close:
- $2.69
- Volume:
- 191534
Company Statistics
- Market Cap.:
- $171.42 million
- Book Value:
- 1.274
- Revenue TTM:
- $432227
- Operating Margin TTM:
- -12179.58%
- Gross Profit TTM:
- $1.25 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -38.17%
- Return on Equity TTM:
- -86.67%
Company Profile
Cue Biopharma had its IPO on 2018-01-02 under the ticker symbol CUE.
The company operates in the Healthcare sector and Biotechnology industry. Cue Biopharma has a staff strength of 51 employees.
Stock update
Shares of Cue Biopharma opened at $2.69 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.65 - $2.77, and closed at $2.72.
This is a +1.12% increase from the previous day's closing price.
A total volume of 191,534 shares were traded at the close of the day’s session.
In the last one week, shares of Cue Biopharma have increased by +1.49%.
Cue Biopharma's Key Ratios
Cue Biopharma has a market cap of $171.42 million, indicating a price to book ratio of 2.5013 and a price to sales ratio of 13.0301.
In the last 12-months Cue Biopharma’s revenue was $432227 with a gross profit of $1.25 million and an EBITDA of $-51738528. The EBITDA ratio measures Cue Biopharma's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cue Biopharma’s operating margin was -12179.58% while its return on assets stood at -38.17% with a return of equity of -86.67%.
In Q1, Cue Biopharma’s quarterly earnings growth was a positive 0% while revenue growth was a negative 81.3%.
Cue Biopharma’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.34 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cue Biopharma’s profitability.
Cue Biopharma stock is trading at a EV to sales ratio of 9.3497 and a EV to EBITDA ratio of -1.9002. Its price to sales ratio in the trailing 12-months stood at 13.0301.
Cue Biopharma stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $81.68 million
- Total Liabilities
- $13.81 million
- Operating Cash Flow
- $15.00 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Cue Biopharma ended 2024 with $81.68 million in total assets and $0 in total liabilities. Its intangible assets were valued at $81.68 million while shareholder equity stood at $55.02 million.
Cue Biopharma ended 2024 with $0 in deferred long-term liabilities, $13.81 million in other current liabilities, 43000.00 in common stock, $-263565000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $56.32 million and cash and short-term investments were $66.20 million. The company’s total short-term debt was $6,295,000 while long-term debt stood at $7.08 million.
Cue Biopharma’s total current assets stands at $68.76 million while long-term investments were $0 and short-term investments were $9.88 million. Its net receivables were $196000.00 compared to accounts payable of $2.15 million and inventory worth $0.
In 2024, Cue Biopharma's operating cash flow was $15.00 million while its capital expenditure stood at $0.
Comparatively, Cue Biopharma paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.72
- 52-Week High
- $5.12
- 52-Week Low
- $2.18
- Analyst Target Price
- $10
Cue Biopharma stock is currently trading at $2.72 per share. It touched a 52-week high of $5.12 and a 52-week low of $5.12. Analysts tracking the stock have a 12-month average target price of $10.
Its 50-day moving average was $3.48 and 200-day moving average was $3.48 The short ratio stood at 1.89 indicating a short percent outstanding of 0%.
Around 442.2% of the company’s stock are held by insiders while 2963.2% are held by institutions.
Frequently Asked Questions About Cue Biopharma
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms’ Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate with Immuno-STAT targeting the KRAS G12V mutation, as well as cancer antigen MAGE-A4; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; and LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.